Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Newer treatments for fibromyalgia syndrome

Authors Richard E Harris, Daniel J Clauw

Published Date December 2008 Volume 2008:4(6) Pages 1331—1342

DOI http://dx.doi.org/10.2147/TCRM.S3396

Published 18 December 2008

Richard E Harris, Daniel J Clauw

Department of Anesthesiology, The University of Michigan, Ann Arbor, MI, USA

Abstract: Fibromyalgia syndrome is a common chronic pain disorder of unknown etiology. The lack of understanding of the pathophysiology of fibromyalgia has made this condition frustrating for patients and clinicians alike. The most common symptoms of this disorder are chronic widespread pain, fatigue, sleep disturbances, difficulty with memory, and morning stiffness. Emerging evidence points towards augmented pain processing within the central nervous system (CNS) as having a primary role in the pathophysiology of this disorder. Currently the two drugs that are approved by the United States Food and Drug Administration (FDA) for the management of fibromyalgia are pregabalin and duloxetine. Newer data suggests that milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, may be promising for the treatment of fibromyalgia. A double-blind, placebo-controlled trial of milnacipran in 125 fibromyalgia patients showed significant improvements relative to placebo. Milnacipran given either once or twice daily at doses up to 200 mg/day was generally well tolerated and yielded significant improvements relative to placebo on measures of pain, patient’s global impression of change in their disease state, physical function, and fatigue. Future studies are needed to validate the efficacy of milnacipran in fibromyalgia.

Keywords: fibromyalgia, pain, pharmacological, treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4361-4369

Published Date: 6 November 2013

Blood–brain barrier: a real obstacle for therapeutics

Shiekh FA

International Journal of Nanomedicine 2012, 7:4065-4067

Published Date: 27 July 2012

Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy

Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM

Pharmacogenomics and Personalized Medicine 2012, 5:19-35

Published Date: 13 January 2012

Corrigendum

Escobar-Chávez JJ, Domínguez-Delgado CL, Rodríguez-Cruz IM

Drug Design, Development and Therapy 2011, 5:487-488

Published Date: 28 November 2011

Corrigendum

Sudenga SL, Royse KE, Shrestha S

Adolescent Health, Medicine and Therapeutics 2011, 2:95-96

Published Date: 15 September 2011

Pazopanib and anti-VEGF therapy

Harry A Drabkin

Research and Reports in Urology 2010, 2:35-40

Published Date: 12 March 2010